{"id":"eu-approved-cosentyx","safety":{"commonSideEffects":[{"rate":"10–15","effect":"Nasopharyngitis"},{"rate":"5–10","effect":"Upper respiratory tract infection"},{"rate":"1–3","effect":"Candida infection (oral/esophageal)"},{"rate":"5–10","effect":"Injection site reactions"},{"rate":"3–5","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL5857501","moleculeType":null,"molecularWeight":"542.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-17A is a pro-inflammatory cytokine produced by T cells that drives inflammation in psoriasis, psoriatic arthritis, and ankylosing spondylitis. By selectively binding and neutralizing IL-17A, Cosentyx reduces the inflammatory cascade and immune cell recruitment to affected tissues, thereby reducing disease symptoms and progression.","oneSentence":"Cosentyx is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated skin and joint diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:46.482Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Non-radiographic axial spondyloarthritis"}]},"trialDetails":[{"nctId":"NCT06630559","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2025-05-26","conditions":"Plaque Psoriasis","enrollment":153},{"nctId":"NCT07054970","phase":"PHASE1","title":"To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2024-01-12","conditions":"Healthy Male Subjects","enrollment":172},{"nctId":"NCT05377944","phase":"PHASE3","title":"Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-10-26","conditions":"Plaque Psoriasis","enrollment":502}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["secukinumab injection"],"phase":"phase_3","status":"active","brandName":"EU-approved Cosentyx","genericName":"EU-approved Cosentyx","companyName":"Celltrion","companyId":"celltrion","modality":"Biologic","firstApprovalDate":"","aiSummary":"Cosentyx is a monoclonal antibody that blocks interleukin-17A (IL-17A), a key inflammatory cytokine involved in immune-mediated skin and joint diseases. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}